115377-94-1

Usage

Uses

Used in Pharmaceutical Industry:
(2-BOC-AMINOPHENYL)BORONIC ACID is used as a key intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new drugs with improved therapeutic properties.
Used in Agrochemical Industry:
(2-BOC-AMINOPHENYL)BORONIC ACID is utilized as a precursor in the production of agrochemicals, enabling the creation of novel compounds with potential applications in agriculture for pest control and crop protection.
Used in Fine Chemicals Production:
(2-BOC-AMINOPHENYL)BORONIC ACID is employed as a building block in the synthesis of fine chemicals, which are essential in various industries such as fragrances, dyes, and specialty chemicals.
Used in Medicinal Chemistry Research:
(2-BOC-AMINOPHENYL)BORONIC ACID is used as a reagent in Suzuki-Miyaura cross-coupling reactions and related transformations, which are crucial for the research and development of new chemical entities with potential medicinal applications.
Used in Drug Discovery:
(2-BOC-AMINOPHENYL)BORONIC ACID is leveraged as a valuable tool in drug discovery processes, where its unique properties can be harnessed to design and synthesize innovative drug candidates with enhanced efficacy and selectivity.

InChI:InChI=1/C11H16BNO4/c1-11(2,3)17-10(14)13-9-7-5-4-6-8(9)12(15)16/h4-7,15-16H,1-3H3,(H,13,14)

Upstream product

• 5570-18-3 2-aminophenylboronic acid 
• 3422-01-3 tert-butyl phenylcarbamate 
• 121-43-7 Trimethyl borate 
• 594-19-4 tert.-butyl lithium 
• 24424-99-5 di-tert-butyl dicarbonate 
• 62-53-3 aniline 

Downstream Products

• 229-87-8 phenanthridine 
• 138590-41-7 (2'-Formyl-biphenyl-2-yl)-carbamic acid tert-butyl ester 
• 1015-89-0 6(5H)-phenanthridinone 
• 177847-08-4 ethyl 3-isopropyl-1-propyl-5-[[2'-(tert-butoxycarbonylamino)-1,1'-biphenyl-4-yl]methyl]-1H-pyrazole-4-carboxylate 
• 192804-45-8 [(3aR,4R,5R,7aR)-7-(2-tert-Butoxycarbonylamino-phenyl)-4-(tert-butyl-dimethyl-silanyloxy)-2,2-dimethyl-3a,4,5,7a-tetrahydro-benzo[1,3]dioxol-5-yl]-carbamic acid benzyl ester 
• 199105-02-7 4-(2-tert-Butoxycarbonylamino-phenyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 299918-29-9 4-(2-tert-butoxycarbonylamino-phenyl)-5-(1-cyano-1-ethyl-propyl)-1-methyl-1H-pyrrole-2-carboxylic acid methyl ester 
• 955123-21-4 [2-(1H-indol-5-yl)-phenyl]-carbamic acid tert-butyl ester 
• 255050-94-3 4-(2-aminophenyl)piperidine 
• 199105-03-8 tert-butyl 4-(2-aminophenyl)piperidine-1-carboxylate 
• 199105-05-0 4-{2-[(Methylsulfonyl)amino]phenyl}-piperidine 
• 199105-08-3 N-Methyl-N-(2-piperidin-4-yl-phenyl)-methanesulfonamide 
• 199105-04-9 tert-Butyl 4-{2-[(methylsulfonyl)amino]phenyl}piperidinecarboxylate 
• 199105-07-2 4-[2-(Methanesulfonyl-methyl-amino)-phenyl]-piperidine-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

Harnessing Cascade Suzuki-Cyclization Reactions of Pyrazolo[3,4-b]pyridine for the Synthesis of Tetracyclic Fused Heteroaromatics

Numerous procedures have been described for the functionalization of pyrazolo[3,4-b]pyridine, mainly involving nucleophilic substitutions at the C-4 position or esterifications/amidations at the C-5 position. In this paper, we describe a robust, easy to implement protocol for the Suzuki cross-coupling reaction of chloroarene 2, followed by in-situ lactonization to provide chromenopyrazolopyridines. The extension of the scope of the reaction to fused naphthyridinones is also reported. This strategy gave access to 10 original pyrazolopyridine-containing tetracyclic compounds.

Synthesis, topoisomerase-targeting activity and growth inhibition of lycobetaine analogs

The plant alkaloid lycobetaine has potent topoisomerase-targeting properties and shows anticancer activity. Based on these findings, several lycobetaine analogs were synthesized mainly differing in their substituents at 2, 8 and 9 position and their biological activities were evaluated. The topoisomerase-targeting properties and cytotoxicity of these structural analogs were assessed in the human gastric carcinoma cell line GXF251L. Performing a plasmid relaxation assay, an increased inhibition of topoisomerase I was found with N-methylphenanthridinium chlorides bearing a 8,9-methylenedioxy moiety or a methoxy group in 2-position. Furthermore, quaternized phenanthridinium derivatives bearing either a 2-methoxy or a 8,9-methylenedioxy moiety in conjunction with a 2-hydroxy or 2-methoxy group display potent topoisomerase II inhibition as shown by decatenation of kinetoplast DNA. In general, the N-methylphenanthridinium chlorides possess more potency in inhibiting topoisomerase I than topoisomerase II. All quaternized derivatives also exhibited potent inhibition of tumor cell growth in the low micromolar concentration range. Hence, N-methylphenanthridinium compounds were found to represent a promising class of compounds, potently inhibiting both, topoisomerases I and II, and may be further developed into clinically useful topoisomerase inhibitors.

Small molecule thienopyrimidine-based protein tyrosine kinase inhibitors

Various thienopyrimidine-based analog compounds are able to selectively inhibit the Src family of tyrosine kinases. These compounds are useful in the treatment of various diseases including hyperproliferative diseases, hematologic diseases, osteoporosis, neurological diseases, autoimmune diseases, allergic/immunological diseases, or viral infections.

Imidazoline derivatives as alpha-1A adrenoceptor ligands

Compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof are disclosed. Such compounds are useful in the treatment of Alpha-1A mediated diseases or conditions such as urinary incontinence.

Dipeptides which promote release of growth hormone

Compounds of formula (I) are growth hormone releasing peptide mimetics which are useful for the treatment and prevention of osteoporosis. STR1

PYRAZOLE DERIVATIVES AS ANGIOTENSIN II ANTAGONISTS

Compounds of general formula I and their salts and solvates are angiotensin II receptor antagonists and as such are useful in the treatment of hypertension, congestive heart failure and elevated intraocular pressure. Pharmaceutical compositions including these compounds and processes for their preparation are also provided.